ArticleActa psychiatrica Scandinavica2026
Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5-Year Follow-Up.
Article in Acta psychiatrica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionWe aimed to investigate the risks of all-cause and cause-specific mortality associated with dose-dependent benzodiazepine and Z-drug (BZDR) use in the Finnish population initiating new BZDR use with five-year follow-up.
methodsStudy subjects were included if BZDR use had started in 2006 with no BZDR dispensing during the preceding years 2004-2005. The information drug dispensing was modeled with PRE2DUP method as time-varying measure updated at every dispensing and then divided into three dose categories which were low dose (< 1.0 Defined Daily Doses [DDDs] per day), medium to high dose (1.0-< 3.0 DDDs/day) and very high-dose (≥ 3.0 DDDs/day). Risk of mortality was studied with Cox regression models.
resultsThe study included 48,124 incident BZDR users aged 18-65 years (44.4% male). During the 5-year follow-up, 2294 (4.9%) individuals died. Compared to non-use periods, BZDRs use was associated with increased mortality risk (adjusted Hazard Ratio HR 1.28, 95% Confidence Interval CI 1.16-1.41). Compared to the time periods when BZDRs were not used, both medium to high-dose use (aHR 1.58, 1.36-1.74) and very-high-dose use (aHR 2.68, 95% CI 2.20-3.26) were associated with an increased risk of all-cause mortality, whereas low dose use was not. The highest risk estimates were observed during very high-dose use and for potentially preventable deaths such as overdoses (aHR 6.18, 95% CI 3.77-10.12), suicides (aHR 4.46, 95% CI 2.79-7.13), and accidents (aHR 3.77, 95% CI 2.66-5.35).
conclusionsPersons using BZDRs in very high doses are at a six-fold increased risk of overdose deaths compared to non-use, and those using BZDRs in medium to high doses are at a three-fold increased risk. In low doses, however, the risk of all-cause mortality was not elevated. The mortality risk strongly associates with higher doses and is often characterized by concomitant use of more than one BZDRs at the same time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.